Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of pasireotide injection in China. Welcome to wholesale bulk high quality pasireotide injection for sale here from our factory. Good service and reasonable price are available.
As an exclusive intervention formulation specifically developed for specific types of Cushing's disease, the core value of Pasireotide Injection is to provide a safe, controllable, and effective intervention pathway for patients who cannot achieve treatment goals after surgery, experience relapse of the condition after surgery, or whose physical conditions are not suitable for surgical operation.
The Cushing's disease suffered by these specific patients is a chronic disease characterized by metabolic disorders of substances in the body. Its root cause is closely related to the abnormal excessive secretion of specific hormones in the body, which can cause a series of chain reactions such as changes in body shape and organ dysfunction, seriously affecting the normal physiological functions and living conditions of patients.
Our Products
|
|
|
Pasireotide COA
 |
||
| Certificate of Analysis | ||
| Compound name | Pasireotide | |
| Grade | Pharmaceutical grade | |
| CAS No. | 396091-73-9 | |
| Quantity | 33g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202601090066 | |
| MFG | Jan 9th 2026 | |
| EXP | Jan 8th 2029 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
| Chemical Formula | C58H66N10O9 |
| Exact Mass | 1046.50 |
| Molecular Weight | 1047.23 |
| m/z | 1046.50 (100.0%), 1047.50 (62.7%), 1048.51 (19.3%), 1047.50 (3.7%), 1049.51 (3.1%), 1048.50 (2.3%), 1048.51 (1.8%), 1049.51 (1.2%) |
| Elemental Analysis | C, 66.52; H, 6.35; N, 13.38; O, 13.75 |
In clinical diagnosis and treatment, although surgical intervention is one of the routine treatment pathways for Cushing's disease, some patients may have special conditions - or the lesion is hidden and difficult to accurately locate, or the tumor infiltration range is wide, which makes it impossible to completely remove the diseased tissue during surgery, or the body is complicated with serious underlying diseases, and the patient is too old to tolerate surgical trauma, ultimately unable to achieve effective relief of the disease through surgery. At this time, targeted drug interventions such as parereotide become the key breakthrough point to improve the condition and control symptoms. By precisely acting on the lesion site, regulating the abnormal secretion state of substances in the body, gradually relieving various physical discomforts caused by the disease, improving the patient's physical function and mental state, and ultimately achieving a steady improvement in quality of life.
Accurate definition of suitable population
The application of Pasireotide Injection peptide has a clear target population and is only suitable for specific types of Cushing's disease patients. Its applicability can be specifically divided into the following three categories, each of which has distinct clinical characteristics and cannot achieve ideal treatment effects through conventional surgery:
Patients who have not achieved clinical remission through surgical intervention. These patients are often affected by hidden lesions, wide tumor infiltration, or incomplete removal of diseased tissue during the surgical operation, resulting in ineffective control of abnormal hormone levels in the body after surgery, and persistent physical manifestations related to the disease that cannot be further improved through secondary surgery. This group of patients is one of the core adapted groups for parereotide intervention.
For those who experience a relapse of their condition after surgery. Although some patients have achieved short-term relief of their symptoms after the initial surgical treatment and their levels of related substances have returned to a reasonable range, during the postoperative follow-up process, the condition may recur, abnormal secretion states may reappear, and the risk of reoperation is high and the benefits are limited. This group of patients can control the progression of their condition and avoid further aggravation of the disease through the intervention of this.
There are patients with surgical tolerance contraindications. These patients are often due to their advanced age, severe organ diseases such as heart, lung, liver, and kidney, or abnormal coagulation function. Their physical conditions cannot tolerate the trauma caused by surgical operations and cannot be treated through surgical methods. It has become an important intervention choice for these patients to alleviate their condition and control symptoms.
Deep analysis of intervention mechanism
The intervention effect of Pasireotide Injection peptide on specific Cushing's disease lies in simulating the natural regulatory substances in the body to achieve precise suppression of abnormal secretion states. Its action pathway is clear and highly specific, which can be carried out from the following three aspects:
Targeting and binding to relevant receptors is crucial. It can accurately identify and bind to specific receptors at the site of the lesion. This binding has a high affinity and can quickly occupy receptor binding sites, blocking the transmission of abnormal signals and laying the foundation for subsequent secretion regulation. Compared to traditional intervention methods, it has stronger targeting and less impact on normal tissues.
It is necessary to curb the release of abnormal substances. By binding to receptors, this can directly inhibit the excessive release of key substances that cause Cushing's disease in diseased tissues, breaking the vicious cycle of "abnormal secretion aggravating the disease", gradually reducing the accumulation of this substance in the body, and alleviating the underlying causes of the disease from the root.
It regulates the homeostasis of substances in the body. As the secretion of abnormal substances decreases, Pareto can further assist in regulating the metabolic balance of related substances in the body, promote the gradual recovery of the body to a normal physiological state, reduce various physical discomforts caused by abnormal substance accumulation, and help patients gradually return to a normal state of life.
Data information source:
Kang Bixing - Xiaoqian Signifor/Pasiretide provides innovative treatment options for patients with Cushing's disease and acromegaly [J]. Kangbixing Overseas Medical, 2025 (7): 1-6
André Lacroix, Feng Gu, Jochen Schopohl, et al. Pasireotide treatment significantly reduces tumor volume in patients with Cushing's disease: results from a Phase 3 study[J]. Pituitary, 2020, 23(3):203-211.
Anonymous. Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease: results from a phase III study[J]. PubMed, 2025, 323(8):5851-5860.
The core manifestation of intervention benefits
The intervention benefits of this in specific patients with Cushing's disease are mainly reflected in three aspects: disease relief, state improvement, and quality of life improvement. Its effects are sustained and stable, and can be divided into the following three points:
The gradual relief of physical abnormalities, as the level of abnormal substances in the body decreases, will gradually improve the discomfort caused by the disease, such as centripetal obesity, abnormal blood pressure, and blood sugar fluctuations. The skin condition, muscle strength, etc. will also gradually recover, reducing the physical pain caused by the disease.
The gradual recovery of substance homeostasis in the body, through precise regulation, can help patients gradually return to normal levels of related substances in the body, break the state of metabolic disorders, reduce the risk of various complications caused by long-term abnormal accumulation of substances, and provide protection for the long-term health of patients.
The significant improvement in quality of life, with the alleviation of symptoms and improvement of physical condition, will optimize the patient's mental state, sleep quality, diet, etc., gradually restoring normal work and life, reducing the psychological burden caused by the disease, and improving overall quality of life.
Data information source:
Endocrinology Branch of Chinese Medical Association Expert Consensus on Diagnosis and Treatment of Cushing's Disease (2025) [J]. Chinese Journal of Endocrinology and Metabolism, 2025, 41 (4): 289-302
In summary, as an exclusive intervention for specific Cushing's disease, Pasireotide Injection provides a safe and effective treatment pathway for patients who cannot be cured by surgery, have postoperative recurrence, or are not suitable for surgery through precise targeted regulatory mechanisms. In clinical applications, by accurately defining the appropriate population and implementing standardized practice guidelines, the intervention advantages can be fully utilized to help patients alleviate symptoms, restore physical stability, and provide important support for the health protection of such patients.
References
Anonymous Interpretation of International Pituitary Society's Consensus on the Diagnosis and Management of Cushing's Disease (Updated Edition) (II) - Drug [J]. Chinese Academy of Sciences Science and Technology Paper Pre release Platform (ChinaXiv), 2022, 1 (7): 1-12
Anonymous. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease[J]. PMC, 2025, 105(9):3462-3470.
Novartis. Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease[J]. Clinical Trials, 2024, 15(6):1-8.
Anonymous Interpretation of the Expert Consensus on the Diagnosis and Treatment of Cushing's Disease (2025) [J]. Douding.com, 2025 (9): 1-15
Hong Kong Global Pharmaceutical Trading Co., Ltd Clinical Application Analysis of Pareto Peptide [J]. Global Medical Information, 2026, 8 (3): 45-48
FAQ
- What is pasireotide used for?
This injection is used to treat Cushing's disease in adults who cannot have surgery or have failed surgery. Pasireotide injection is also used for the treatment of acromegaly (a growth hormone disorder) in patients who cannot be treated with surgery. Signifor® is available only with your doctor's prescription.
- What is the difference between octreotide and pasireotide?
Octreotide is a specific SST2 receptor agonist, whereas pasireotide is a pan-somatostatinergic agonist [9]. We demonstrated for the first time that pasireotide induces a higher reduction in cell viability and stronger inhibitory effect on cell proliferation than octreotide in meningiomas in primary cell cultures.
- Is pasireotide safe to use long-term?
Long‐acting pasireotide provided sustained biochemical improvements and clinical benefit in a significant proportion of patients with CD and was generally well tolerated, with no new safety signals emerging over long‐term treatment.
Hot Tags: pasireotide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale